Abstract
Current treatment of children with juvenile chronic arthritis (JCA) has been changed significantly by the results of randomized controlled trials (RCTs). However, due to low market appeal of JCA, few RCTs are being funded by drug companies and none in the more rare childhood rheumatic diseases, in addition, RCTs have several limitations when used for a chronic illness such as JCA. To deal with this situation, the Pediatric Rheumatology International Trials Organization (PRINTO) is being organized to perform effectiveness trials in addition to efficacy trials in a variety of paediatric rheumatic illnesses.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
